Trial Profile
A Retrospective Study of Apixaban and Rivaroxaban in Cancer-Associated Venous Thromboembolism (CA-VTE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 12 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology